HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma
Provided By GlobeNewswire
Last update: Mar 21, 2025
— First and only EZH2 inhibitor approved by the NMPA —
— HUTCHMED’s fourth product, and its first approval in hematological malignancies —
Read more at globenewswire.com
